SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-014380
Filing Date
2024-04-12
Accepted
2024-04-12 06:04:46
Documents
18
Period of Report
2024-04-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 56372
2 ex4-1.htm EX-4.1 116627
3 ex10-1.htm EX-10.1 284035
4 ex10-2.htm EX-10.2 183359
5 ex99-1.htm EX-99.1 11188
6 ex99-2.htm EX-99.2 88174
  Complete submission text file 0001493152-24-014380.txt   1048838

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE ocx-20240411.xsd EX-101.SCH 3012
8 XBRL LABEL FILE ocx-20240411_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE ocx-20240411_pre.xml EX-101.PRE 22358
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3471
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

IRS No.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 24839874
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)